GLP-1 RAs produce significant weight loss in adults without diabetes, with newer treatments showing greater results

Every year there's a new 'greatest' shot on the market. Last year's greatest is already in the rearview.

An updated systematic review evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and coagonists among adults with overweight or obesity without diabetes found that, among currently available treatments, tirzepatide produced the greatest weight loss, while newer experimental drugs showed even larger effects.

Read it at Medical Xpress ↗

← Front page